EcoDrugPlus

Microtubule Associated Protein Tau

Ensembl ID : ENSMPUG00000008117
Gene Symbol: MAPT
2 Cross references
255 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSMPUG00000003144
Gene Symbol: MAPK1
2 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSMPUG00000002290
Gene Symbol: MAPK10
2 Cross references
147 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSMPUG00000002272
Gene Symbol: MAPK11
2 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSMPUG00000003927
Gene Symbol: MAPK14
2 Cross references
276 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSMPUG00000012636
Gene Symbol: MAPK3
2 Cross references
196 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSMPUG00000009129
Gene Symbol: MAPK8
2 Cross references
294 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSMPUG00000000593
Gene Symbol: MAPK9
2 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSMPUG00000000363
Gene Symbol: MAP2K1
2 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSMPUG00000004715
Gene Symbol: MAP2K2
1 Cross references
263 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSMPUG00000007493
Gene Symbol: MAP3K1
2 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSMPUG00000017712
Gene Symbol: MAP3K10
2 Cross references
185 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).